Alcon acquires Belkin Vision, direct selective laser trabeculoplasty device
Click Here to Manage Email Alerts
Alcon completed the acquisition of Belkin Vision, including its direct selective laser trabeculoplasty technology, according to a press release.
“While global glaucoma treatment guidelines and practice are shifting towards more first-line use of SLT, practical challenges have limited it from becoming more widely used as a primary therapy,” Sean Clark, president of global surgical franchise at Alcon, told Healio. “DSLT delivers precise treatment in a patient- and physician-friendly experience, and leveraging Alcon’s footprint as the global leader in eye care will help broaden access to this exciting technology.”
The deal was closed with a total upfront consideration of $81 million, including a cash payment of approximately $65 million, with sales-based milestones potentially reaching up to $385 million.
The direct selective laser trabeculoplasty (DSLT) device previously received 510(k) clearance from the FDA, although it is not yet available in the United States, and was approved in the European Union and the United Kingdom. It is designed to deliver laser energy to the trabecular meshwork while eliminating the need for a gonio lens or manual aiming through its proprietary eye-tracking technology, the release said.
The acquisition expands Alcon’s glaucoma portfolio, and the company is aiming to make the DSLT device available in the U.S. later this year.
Collapse
Read more about
Click Here to Manage Email Alerts